This article is more than 5 years old. Information may no longer be current.

VIDEO: Findings support development of staphylococcal enterotoxin B protein vaccine

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BALTIMORE — Wilber Chen, MD, associate professor of medicine at the University of Maryland School of Medicine, discusses findings from a phase 1 trial evaluating the safety and immunogenicity of a parenterally administered recombinant staphylococcal enterotoxin B protein vaccine named STEBVax, which may lead to a useful treatment for toxic shock syndrome. Results from preclinical studies were sufficient to warrant human trials, according to Chen, who says the vaccine was safe and nonreactogenic at dosages of up to 20 μg.

Disclosure: Chen reports receiving grants for clinical research from PaxVax, Inc.